These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 3275556)
1. Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes. Reaven GM; Chang H; Hoffman BB Diabetes; 1988 Jan; 37(1):28-32. PubMed ID: 3275556 [TBL] [Abstract][Full Text] [Related]
2. Lowering of plasma glucose in diabetic rats by antilipolytic agents. Reaven GM; Chang H; Ho H; Jeng CY; Hoffman BB Am J Physiol; 1988 Jan; 254(1 Pt 1):E23-30. PubMed ID: 2962514 [TBL] [Abstract][Full Text] [Related]
3. Glucose tolerance and blood pressure are improved in the spontaneously hypertensive rat by ethyl-2-(6-(4-chlorophenoxy)-hexyl)oxirane-2-carboxylate (etomoxir), an inhibitor of fatty acid oxidation. Swislocki A; Eason T Am J Hypertens; 1994 Aug; 7(8):739-44. PubMed ID: 7986465 [TBL] [Abstract][Full Text] [Related]
4. Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue. Oh YT; Oh KS; Choi YM; Jokiaho A; Donovan C; Choi S; Kang I; Youn JH Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1012-21. PubMed ID: 21386057 [TBL] [Abstract][Full Text] [Related]
5. Effect of fatty acid oxidation inhibition on glucose metabolism in diabetic rats. Collier GR; Traianedes K; Macaulay SL; O'Dea K Horm Metab Res; 1993 Jan; 25(1):9-12. PubMed ID: 8428713 [TBL] [Abstract][Full Text] [Related]
6. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303 [TBL] [Abstract][Full Text] [Related]
7. Dexamethasone-induced impairment in skeletal muscle glucose transport is not reversed by inhibition of free fatty acid oxidation. Venkatesan N; Lim J; Bouch C; Marciano D; Davidson MB Metabolism; 1996 Jan; 45(1):92-100. PubMed ID: 8544783 [TBL] [Abstract][Full Text] [Related]
8. Co-administration of etomoxir and RU-486 mitigates insulin resistance in hepatic and muscular tissues of STZ-induced diabetic rats. Bitar MS Horm Metab Res; 2001 Oct; 33(10):577-84. PubMed ID: 11607876 [TBL] [Abstract][Full Text] [Related]
9. Glucose kinetics during acute and chronic treatment of rats with 2[6(4-chloro-phenoxy)hexyl]oxirane-2-carboxylate, etomoxir. Kruszynska YT; Sherratt HS Biochem Pharmacol; 1987 Nov; 36(22):3917-21. PubMed ID: 3689429 [TBL] [Abstract][Full Text] [Related]
10. Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats. Blachère JC; Pérusse F; Bukowiecki LJ Metabolism; 2001 Aug; 50(8):945-51. PubMed ID: 11474483 [TBL] [Abstract][Full Text] [Related]
11. Etomoxir, sodium 2-[6-(4-chlorophenoxy)hexyl] oxirane-2-carboxylate, inhibits triacylglycerol depletion in hepatocytes and lipolysis in adipocytes. Spurway TD; Pogson CI; Sherratt HS; Agius L FEBS Lett; 1997 Mar; 404(1):111-4. PubMed ID: 9074648 [TBL] [Abstract][Full Text] [Related]
12. Effect of exercise and diet on triglyceride metabolism in rats with moderate insulin deficiency. Dall'Aglio E; Chang F; Chang H; Stern J; Reaven G Diabetes; 1983 Jan; 32(1):46-50. PubMed ID: 6336702 [TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Oakes ND; Thalén PG; Jacinto SM; Ljung B Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421 [TBL] [Abstract][Full Text] [Related]
14. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes. Reed MJ; Meszaros K; Entes LJ; Claypool MD; Pinkett JG; Brignetti D; Luo J; Khandwala A; Reaven GM Diabetologia; 1999 Jan; 42(1):102-6. PubMed ID: 10027587 [TBL] [Abstract][Full Text] [Related]
15. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Wang W; Basinger A; Neese RA; Shane B; Myong SA; Christiansen M; Hellerstein MK Am J Physiol Endocrinol Metab; 2001 Mar; 280(3):E540-7. PubMed ID: 11171611 [TBL] [Abstract][Full Text] [Related]
16. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir. Schmitz FJ; Rösen P; Reinauer H Horm Metab Res; 1995 Dec; 27(12):515-22. PubMed ID: 8750778 [TBL] [Abstract][Full Text] [Related]
17. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Lopaschuk GD; Wall SR; Olley PM; Davies NJ Circ Res; 1988 Dec; 63(6):1036-43. PubMed ID: 3197271 [TBL] [Abstract][Full Text] [Related]
18. A fatty acid-induced decrease in pyruvate dehydrogenase activity is an important determinant of beta-cell dysfunction in the obese diabetic db/db mouse. Zhou YP; Berggren PO; Grill V Diabetes; 1996 May; 45(5):580-6. PubMed ID: 8621007 [TBL] [Abstract][Full Text] [Related]
19. The effect of etomoxir on insulin sensitivity in type 2 diabetic patients. Hübinger A; Weikert G; Wolf HP; Gries FA Horm Metab Res; 1992 Mar; 24(3):115-8. PubMed ID: 1577399 [TBL] [Abstract][Full Text] [Related]
20. Effects of oral hypoglycemic agent methylpalmoxirate on exercise capacity of streptozocin diabetic rats. Young JC; Treadway JL; Fader EI; Caslin RF Diabetes; 1986 Jul; 35(7):744-8. PubMed ID: 3721061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]